arrow
M

Morgane Cheminant

necker-enfants malades university hospital
H指数:24
被引数:2,015

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis

二线阿西美单抗 ciloleucel 在不适合移植的大B细胞淋巴瘤中的最终分析

2026-09-230
OAAI
Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort

套细胞淋巴瘤的现代治疗与生存结局:来自REALYSA(LYSA队列)的国家真实世界分析

2026-09-220
OAAI
Expanding the clinical spectrum of RNU4ATAC-opathies: More frequent and diverse than assumed

扩展RNU4ATAC-opathies的临床谱:比预想的更频繁和多样

2026-06-190
OA
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study

原发纵隔大B细胞淋巴瘤中循环肿瘤DNA的 interim assessment:一项多中心LYSA研究

2026-04-160
OA
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma
2026-01-130
OAAI
IgA and IgM-enriched Immunoglobulins in Primary Immunodeficiencies: a Pilot Study

IgA和IgM富集的免疫球蛋白在原发性免疫缺陷病中的研究:一项初步研究

2025-11-280
OAAI
Consecutive non-Aspergillus Fungal Invasive Infections in Chronic Granulomatous Disease: Data from the French National Reference Center for Primary ImmunoDeficiencies and literature review

连续的非曲霉菌真菌侵袭性感染在慢性肉芽肿病中的研究:来自法国原发性免疫缺陷病国家参考中心的数据及文献综述

2025-11-060
OAAI
Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group

抗CD19 CAR-T细胞疗法失败后套细胞淋巴瘤患者的结局:Descar-T研究(Lysa集团)

2025-10-030
OAAI
The impact of allogeneic hematopoietic stem cell transplantation on pulmonary complications in adults with inborn errors of immunity

同种异基因造血干细胞移植对免疫缺陷成人肺部并发症的影响

2025-05-140
OAAI
Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study

SOCS1缺乏个体的临床表现、疾病外显率及治疗:一项基于注册和人群的研究

2025-02-010
OAAI
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA

抗PD1疗法在结外NK/T细胞淋巴瘤中的疗效:一项来自LYSA的匹配队列分析

2025-01-200
OA
Dupilumab in atopic-dermatitis-like eczema associated with inborn errors of immunity: A nationwide study
2025-01-010
PRE
Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

p16的异常细胞质表达是接受一线阿糖胞苷为基础的免疫化疗的年轻MCL患者的一个新的强预后标志物,一项来自Lysa Group、Nordic Lymphoma Group和European MCL Network的研究

BLOOD
IF23.1
2024-11-050
PRE
Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

抗CD19 CAR T细胞疗法失败后滤泡性淋巴瘤患者的结局:Lysa Group的Descar-T研究

BLOOD
IF23.1
2024-11-050
PRE
Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study

基线18F-FDG PET/CT小脑/肝脏指数改善移植后淋巴增生性疾病预后的多中心回顾性研究

2024-05-270
OAAI
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial( vol 29 , pg 2593 , 2023)

Axicabtagene ciloleucel作为不适合自体干细胞移植的大b细胞淋巴瘤的二线治疗: 一项2期试验 (第29卷,2593页,2023页)

2024-05-140
OAAI
Increased Risk of Invasive Aspergillosis in Immunocompromised Patients With Persistent SARS-CoV-2 Viral Shedding >8 Weeks, Retrospective Case-control Study

持续性SARS-CoV-2病毒脱落> 8周的免疫功能低下患者侵袭性曲霉病风险增加,回顾性病例对照研究

2024-01-091
OAAI
Combined germline and somatic human FADD mutations cause autoimmune lymphoproliferative syndrome

结合种系和体细胞人FADD突变导致自身免疫性淋巴增生综合征

2024-01-017
PRE
Severe adult hemophagocytic lymphohistiocytosis (HLHa) correlates with HLH-related gene variants

严重成人噬血细胞性淋巴组织细胞增生症 (HLHa) 与HLH相关基因变异相关

2024-01-016
OAAI